Wegovy produces some “magical” results for weight loss, but we might just be at the surface of what these drugs can achieve.
Illustration: The Lamen
The new trial underscores the connection between obesity and heart health. Not just about body fat, it triggers a biochemical cascade associated with cardiovascular disease, diabetes, hypertension, stroke, obstructive sleep apnea, and even some cancers.
It’s not clear how semaglutide reduces the risk of a serious cardiovascular event. These GLP-1 receptor agonists have shown benefits on blood pressure, inflammation, and the inner lining of blood vessels, which could explain the protective effect.
What’s next: As the full publication of the study follows, Novo Nordisk expects broader approval for Wegovy for treating a number of health conditions. Experts also expect these results to advocate for better coverage of the drug under insurance, as the $1,300-a-month price has kept it inaccessible for many.